Tumor suppressor candidate 3 (TUSC3) inhibited tumorigenesis in ovarian cancer, prostate cancer, glioblastoma and pancreatic cancer but enhanced cancer progression in head and neck cancer and CRC (39). Here, TUSC3 is linked to pancreatic neoplasm.